Investor Overview DPortfolio includes a robust line of NCEs (New Chemical Entities) and medicines based on compounds found in psychedelics, including four lead clinical trial drug candidates DExclusive partnership with Applied Pharmaceutical Innovation provides access to a world-class, end-to-end drug development infrastructure under one roof DTeam of highly experienced chemists, doctors and scientists specialized in pharmaceutical chemistry, natural products chemistry and drug development DFive-year master collaboration research agreement with Johns Hopkins University to research novel psychedelic therapies for mental health and addiction disorders DResearch out of Johns Hopkins has shown promising efficacy data using psilocybin as a smoking cessation treatment with an 80% abstinence rate at six months DOnly industry sponsored clinical trial assessing psilocybin for smoking cessation DLead drug candidate, MYCO-001, is being supplied for a multi-site NIDA (National Institute on Drug Abuse) grant-funded smoking cessation study, marking the first time in over 50 years that the U.S. government has funded a study of a psychedelic compound
RkJQdWJsaXNoZXIy NDMyMDk=